Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 720 for:    Botulinum Toxins, Type A

Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleft Lip Repair by Modified Millard Cheiloplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03047499
Recruitment Status : Unknown
Verified February 2017 by Mostafa Khairy, Cairo University.
Recruitment status was:  Recruiting
First Posted : February 9, 2017
Last Update Posted : February 9, 2017
Sponsor:
Information provided by (Responsible Party):
Mostafa Khairy, Cairo University

Brief Summary:
Evaluation of the effect of botulinum toxin type-A injection prior to surgical correction of complete unilateral cleftlip repair by modified millard cheiloplasty

Condition or disease Intervention/treatment
Esthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair Drug: Botulinum toxin type A

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 6 Months
Official Title: Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleftlip Repair by Modified Millard Cheiloplasty
Estimated Study Start Date : February 15, 2017
Estimated Primary Completion Date : October 15, 2017
Estimated Study Completion Date : November 15, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Scar Length Drug: Botulinum toxin type A
Botulinum toxin type-A injection

Vancouver scar scale Drug: Botulinum toxin type A
Botulinum toxin type-A injection

Scar width Drug: Botulinum toxin type A
Botulinum toxin type-A injection




Primary Outcome Measures :
  1. Scar Length [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months to 6 Months   (Child)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Children up to 6 months
Criteria

Inclusion Criteria:

  • Primary cleft lip

Exclusion Criteria:

  • Cleft palate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03047499


Contacts
Layout table for location contacts
Contact: Mostafa Ayman Khairy 00201001155527 mostafakhairy100@hotmail.com

Locations
Layout table for location information
Egypt
Cairo University Recruiting
Cairo, Egypt, 72427
Contact: Rehab Tariq Elsharkawy, Dr         
Sponsors and Collaborators
Mostafa Khairy

Additional Information:

Layout table for additonal information
Responsible Party: Mostafa Khairy, Cairo University
ClinicalTrials.gov Identifier: NCT03047499     History of Changes
Other Study ID Numbers: CEBC-CU-2017-02-04
First Posted: February 9, 2017    Key Record Dates
Last Update Posted: February 9, 2017
Last Verified: February 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A
Cleft Lip
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Mouth Abnormalities
Stomatognathic System Abnormalities
Congenital Abnormalities
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents